Treating Multiple Myeloma in Latin America and Canada
Emerging and Practical Concepts in Multiple Myeloma
Overview
In recent years, progress in the understanding of multiple myeloma has led to novel therapies that are rapidly changing treatment paradigms. Aptitude Health developed the Global Multiple Myeloma Academy to help physicians who treat multiple myeloma bridge the gap between innovation and implementation of patient care.
Date and Location
18–19 June 2021, Virtual Meeting
Faculty
Rafael Fonseca, MD
Mayo Clinic Cancer Center, USA
Irene Ghobrial, MD
Dana-Farber Cancer Institute, USA
Vania Hungria, MD, PhD
São Germano Clinic, São Paulo, Brazil
Humberto Martínez Cordero, MD
National Cancer Institute, Bogotá, Colombia
María-Victoria Mateos, MD, PhD
University of Salamanca, Spain
Natalia Schütz, MD, MS
Instituto Universitario del Hospital Italiano de Buenos Aires, Argentina
Keith Stewart, MD
Princess Margaret Cancer Centre, Canada
Jorge Vela-Ojeda, MD, PhD
Hospital de Especialidades CMN La Raza, IMSS, Mexico City, Mexico
|
Agenda |
This virtual program was held over 2 days. Day 1: Minimal Residual Disease, Frontline Therapies, and the Role of Transplantation Day 2: Management of High-Risk, Relapsed, and Heavily Pretreated Multiple Myeloma, New and Future Therapies, and Patient Case Discussion |
Day 1: Friday, June 18, 2021
6.00 PM – 8.45 PM Rio time (UTC-3)
| Time (UTC -3) | Topic | Speaker |
| 6.00 PM – 6.15 PM | Welcome and Meeting Overview | Rafael Fonseca |
| 6.15 PM – 6.35 PM | Smoldering Multiple Myeloma • Diagnosis, criteria, and when and how to intervene |
Irene Ghobrial |
| 6.35 PM – 6.55 PM | Role of Minimal Residual Disease in Multiple Myeloma • Prognostic value, clinical relevance, and MRD-driven therapeutic guidance |
Rafael Fonseca |
| 6.55 PM – 7.15 PM | Frontline Therapy for Newly Diagnosed Transplant-Eligible Multiple Myeloma: The Role of Transplantation • Guidelines, induction therapies, and how and when to transplant |
Vania Hungria |
| 7.15 PM – 7.30 PM | Break | |
| 7.30 PM – 7.50 PM | Optimal Use of Consolidation and Maintenance Therapy • Evolving insights in consolidation and maintenance treatment after transplant |
Jorge Vela-Ojeda |
| 7.50 PM – 8.15 PM | Frontline Therapy for Newly Diagnosed Transplant-Ineligible Patients • Criteria, guidelines, and treatment choices |
Keith Stewart |
| 8.15 PM – 8.30 PM | Patient Case Discussion: Newly Diagnosed + Relapsed/Refractory Multiple Myeloma | Eloísa Riva |
| 8.30 PM – 8.45 PM | Session Close | Rafael Fonseca |
Day 2: Saturday, June 19, 2021
6.00 PM – 9.30 PM Rio time (UTC-3)
| Time (UTC-3) | Topic | Speaker |
| 6.00 PM – 6.10 PM | Session Open | Rafael Fonseca |
| 6.10 PM – 6.30 PM | Identification and Special Considerations for High-Risk Multiple Myeloma • Risk stratification, prognosis, and treatment choices |
María-Victoria Mateos |
| 6.30 PM – 6.55 PM | Management of Early Relapse of Multiple Myeloma • Definition, prognosis, and treatment choices |
Rafael Fonseca |
| 6.55 PM – 7.20 PM | Management of Heavily Pretreated Multiple Myeloma • Optimal use of treatment choices in relapsed/refractory multiple myeloma, excluding T-cell engagers |
Keith Stewart |
| 7.20 PM – 7.30 PM | Break | |
| 7.30 PM – 8.20 PM | New and Future Therapies for Multiple Myeloma • Promising new developments in relapsed/refractory MM • Latest trial updates and upcoming new strategies; focus on BCMA-directed therapies |
Irene Ghobrial |
| 8.20 PM – 9.15 PM | Patient Case Discussion: Relapsed/Refractory Multiple Myeloma • Cases from the region will be discussed with the faculty – “tumor board approach” • Relapsed/refractory MM, treatment challenges in the region – Natalia Schütz (Arg) ‒ Case 1: Cristian Seehaus and Natalia Schütz (Arg) ‒ Case 2: Ana Luiza Miranda Silva Días and Vania Hungria (Bras) ‒ Case 3: Didier Larios Sanjuan and Humberto Martínez-Cordero (Col) ‒ Case 4: Sofía Sánchez and Jorge Vela-Ojeda (Mex) |
All faculty |
| 9.15 PM – 9.30 PM | Session Close | Rafael Fonseca |
